Stock listing
KRX:389650 Nextbiomedical Co. Ltd. (넥스트바이오메디컬) 주가
Follow Nextbiomedical Co. Ltd. into a list and get an email when it puts out news.
Share price · KRX:389650
₩23,800 KRW -100 (-0.4%)
Close on Nov 20, 2026
- Day range
- ₩23,800 – ₩24,700 KRWNov 20, 2026
- Volume
- 12,162 sharesNov 20, 2026
- Market cap
- ₩197.0B KRWAt the close on Nov 20, 2026 · price × 8.28M shares outstanding
- 52-week range
- ₩22,900 – ₩101,000 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩741.9M KRWMedian day 22,169 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:389650 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩23,800 | -100 | -0.4% | ₩24,700 | ₩24,700 | ₩23,800 | 12,162 | |
| ₩23,900 | +450 | +1.9% | ₩23,600 | ₩24,600 | ₩23,250 | 9,755 | |
| ₩23,450 | -350 | -1.5% | ₩23,200 | ₩24,250 | ₩22,900 | 27,318 | |
| ₩23,800 | -2,500 | -9.5% | ₩26,350 | ₩26,750 | ₩23,800 | 30,776 | |
| ₩26,300 | -1,350 | -4.9% | ₩27,650 | ₩28,900 | ₩26,150 | 22,183 | |
| ₩27,650 | -1,350 | -4.7% | ₩28,550 | ₩29,500 | ₩27,400 | 18,913 | |
| ₩29,000 | +650 | +2.3% | ₩28,300 | ₩29,950 | ₩28,300 | 18,973 | |
| ₩28,350 | +1,850 | +7.0% | ₩27,200 | ₩28,350 | ₩26,850 | 15,675 | |
| ₩26,500 | -1,050 | -3.8% | ₩27,500 | ₩28,000 | ₩26,350 | 22,822 | |
| ₩27,550 | -1,000 | -3.5% | ₩26,900 | ₩28,450 | ₩26,250 | 22,011 | |
| ₩28,550 | -750 | -2.6% | ₩29,600 | ₩30,400 | ₩28,000 | 17,639 | |
| ₩29,300 | -150 | -0.5% | ₩29,500 | ₩30,600 | ₩27,700 | 32,549 | |
| ₩29,450 | +800 | +2.8% | ₩28,300 | ₩30,250 | ₩28,000 | 36,631 | |
| ₩28,650 | +1,500 | +5.5% | ₩27,000 | ₩28,800 | ₩27,000 | 17,747 | |
| ₩27,150 | -1,200 | -4.2% | ₩28,500 | ₩28,650 | ₩26,900 | 31,469 | |
| ₩28,350 | -950 | -3.2% | ₩28,850 | ₩29,050 | ₩28,350 | 15,176 | |
| ₩29,300 | +1,300 | +4.6% | ₩28,550 | ₩29,500 | ₩27,950 | 35,665 | |
| ₩28,000 | +850 | +3.1% | ₩27,750 | ₩29,300 | ₩27,500 | 24,337 | |
| ₩27,150 | -50 | -0.2% | ₩26,900 | ₩28,000 | ₩26,500 | 12,396 | |
| ₩27,200 | +750 | +2.8% | ₩25,600 | ₩27,200 | ₩25,200 | 23,247 | |
| ₩26,450 | -1,250 | -4.5% | ₩27,750 | ₩28,000 | ₩26,200 | 19,026 | |
| ₩27,700 | +700 | +2.6% | ₩27,200 | ₩29,050 | ₩27,000 | 25,380 | |
| ₩27,000 | -800 | -2.9% | ₩27,100 | ₩28,350 | ₩26,400 | 42,122 | |
| ₩27,800 | +1,450 | +5.5% | ₩25,550 | ₩27,800 | ₩25,550 | 14,362 | |
| ₩26,350 | +800 | +3.1% | ₩25,400 | ₩27,200 | ₩25,400 | 19,552 | |
| ₩25,550 | -1,350 | -5.0% | ₩25,450 | ₩26,400 | ₩25,150 | 27,456 | |
| ₩26,900 | -400 | -1.5% | ₩27,100 | ₩27,750 | ₩26,800 | 29,309 | |
| ₩27,300 | -900 | -3.2% | ₩27,900 | ₩28,000 | ₩26,450 | 29,745 | |
| ₩28,200 | -1,500 | -5.1% | ₩29,500 | ₩29,650 | ₩28,150 | 30,197 | |
| ₩29,700 | -1,800 | -5.7% | ₩31,000 | ₩31,000 | ₩28,250 | 58,218 | |
| ₩31,500 | 0 | 0.0% | ₩31,600 | ₩32,050 | ₩31,200 | 7,526 | |
| ₩31,500 | -250 | -0.8% | ₩31,750 | ₩32,600 | ₩31,100 | 17,419 | |
| ₩31,750 | -1,450 | -4.4% | ₩33,100 | ₩33,400 | ₩31,600 | 21,520 | |
| ₩33,200 | +750 | +2.3% | ₩32,600 | ₩33,850 | ₩31,400 | 49,129 | |
| ₩32,450 | +1,800 | +5.9% | ₩30,750 | ₩32,950 | ₩30,600 | 37,254 | |
| ₩30,650 | -700 | -2.2% | ₩31,800 | ₩31,800 | ₩30,300 | 13,918 | |
| ₩31,350 | -1,050 | -3.2% | ₩32,700 | ₩33,050 | ₩31,350 | 25,308 | |
| ₩32,400 | +4,100 | +14.5% | ₩28,450 | ₩33,450 | ₩28,150 | 75,810 | |
| ₩28,300 | -350 | -1.2% | ₩28,550 | ₩29,400 | ₩28,300 | 25,180 | |
| ₩28,650 | 0 | 0.0% | ₩28,800 | ₩30,200 | ₩28,400 | 19,196 | |
| ₩28,650 | -1,000 | -3.4% | ₩29,600 | ₩30,000 | ₩28,650 | 17,874 | |
| ₩29,650 | +450 | +1.5% | ₩29,000 | ₩30,100 | ₩29,000 | 16,528 | |
| ₩29,200 | -950 | -3.2% | ₩30,050 | ₩30,050 | ₩28,700 | 13,473 | |
| ₩30,150 | +750 | +2.6% | ₩30,000 | ₩32,150 | ₩29,950 | 74,337 | |
| ₩29,400 | -100 | -0.3% | ₩28,700 | ₩30,150 | ₩28,650 | 15,810 | |
| ₩29,500 | -50 | -0.2% | ₩29,250 | ₩29,750 | ₩28,550 | 18,033 | |
| ₩29,550 | -850 | -2.8% | ₩30,400 | ₩30,450 | ₩29,550 | 18,979 | |
| ₩30,400 | -50 | -0.2% | ₩30,450 | ₩30,950 | ₩30,200 | 9,258 | |
| ₩30,450 | -600 | -1.9% | ₩30,850 | ₩31,800 | ₩30,050 | 22,154 | |
| ₩31,050 | 0 | 0.0% | ₩31,050 | ₩31,250 | ₩30,500 | 12,201 | |
| ₩31,050 | -50 | -0.2% | ₩31,100 | ₩31,800 | ₩30,600 | 29,493 | |
| ₩31,100 | -900 | -2.8% | ₩32,300 | ₩32,800 | ₩31,000 | 18,502 | |
| ₩32,000 | -1,350 | -4.0% | ₩32,800 | ₩34,300 | ₩31,950 | 25,897 | |
| ₩33,350 | +150 | +0.5% | ₩32,900 | ₩34,500 | ₩32,200 | 22,692 | |
| ₩33,200 | +200 | +0.6% | ₩32,400 | ₩33,225 | ₩31,100 | 24,864 | |
| ₩33,000 | -450 | -1.3% | ₩33,050 | ₩33,450 | ₩31,950 | 18,750 | |
| ₩33,450 | -100 | -0.3% | ₩33,100 | ₩33,800 | ₩32,650 | 22,823 | |
| ₩33,550 | +600 | +1.8% | ₩32,750 | ₩33,700 | ₩32,000 | 17,727 | |
| ₩32,950 | -300 | -0.9% | ₩33,000 | ₩33,100 | ₩31,050 | 16,751 | |
| ₩33,250 | +950 | +2.9% | ₩33,300 | ₩33,300 | ₩31,800 | 23,571 | |
| ₩32,300 | -2,200 | -6.4% | ₩34,000 | ₩34,000 | ₩31,150 | 46,251 | |
| ₩34,500 | +1,400 | +4.2% | ₩34,350 | ₩34,850 | ₩33,000 | 33,096 |
- Ticker
- KRX:389650
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- KRX
- Currency
- KRW
What changed lately
Latest news release · Jul 6, 2026
Nexsphere-F™ Clinical Study Published in Radiology, Showing 57% Reduction in Knee Osteoarthritis Pain
Latest news
Nexsphere-F™ Clinical Study Published in Radiology, Showing 57% Reduction in Knee Osteoarthritis Pain
Jul 6, 2026
Closed ₩41,300 (+2.2%) on Jul 7, 2026
Nextbiomedical Co. Ltd. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 1 in the last 12 months · 3 in all · newest Jul 6, 2026 · oldest 2025
Valuation
P/E 847× against a median of 30.6×: the highest of 6 Medical devices & supplies companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩162.6B KRW
- P/E
- 847×
- EV/sales
- 9.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.0×
- Gross margin
- 70.5%
- Operating margin
- −12.9%
- Net margin
- 1.3%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Nextbiomedical Co. Ltd. · KRX:389650 | US$146.4M | US$120.9M | 847× | 9.1× | n/a | 4.0× | 1.3% | 0.0× | n/a |
| Pacific Hospital Supply Co., Ltd. · TPEX:4126 | US$158.8M | US$116.7M | 12.1× | 1.6× | 6.3× | 1.8× | 17.9% | 0.0× | n/a |
| PW Medtech Group Ltd. · HKEX:1358 | US$156.6M | −US$114.6M | 11.1× | −0.9× | −2.9× | 0.3× | 11.5% | 0.0× | n/a |
| CUREXO Inc. · KRX:060280 | US$152.5M | US$133.1M | 37.2× | 2.3× | 29.7× | 2.0× | 7.1% | 0.0× | n/a |
| Delta Asia International Corporation · TPEX:6762 | US$151.3M | US$152.0M | 213× | 7.2× | 18.2× | 3.8× | 3.4% | 0.2× | n/a |
| KORU Medical Systems, Inc. · NASDAQ:KRMD | US$147.3M | US$3.17T | n/a | 68,440× | 15,926,569× | 7.6× | −1.8% | 163,275× | 1.06 |
| Paxman AB · OMXSTO:PAX | US$146.5M | US$137.3M | n/a | 3.8× | 36.9× | 3.6× | −1.4% | 0.0× | n/a |
| TriSalus Life Sciences, Inc. · NASDAQ:TLSI | US$143.1M | US$134.5M | n/a | 2.9× | n/a | 211× | −56.6% | 47.6× | 1.22 |
| Inogen, Inc · NASDAQ:INGN | US$140.7M | US$58.75M | n/a | 0.2× | n/a | 0.9× | −10.1% | 0.1× | 0.64 |
| Asterasys Co., Ltd. · KRX:450950 | US$138.3M | US$124.7M | 30.6× | 4.2× | 26.8× | 4.1× | 15.4% | 0.0× | n/a |
| Hans Biomed Corp · KRX:042520 | US$135.1M | US$125.0M | n/a | 1.4× | n/a | 2.3× | −15.8% | 0.1× | n/a |
| Median of the others | US$146.9M | US$129.1M | 30.6× | 2.6× | 26.8× | 3.0× | 1.0% | 0.1× | 1.06 |
Forecasts
Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- Price target
- 77500.00 KRW · Analysts' mean
- EPS, year to Dec 2026
- -351.00 · 2 analysts
- Revenue, year to Dec 2026
- 22.33B · 3 analysts
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 16.5B | 9.54B | 4.88B | 2.80B | 2.27B |
| Cost of revenue | 4.95B | 3.72B | 2.77B | 2.51B | 2.89B |
| Gross profit | 11.5B | 5.82B | 2.11B | 284.5M | -624.8M |
| Research and development | 7.58B | 6.62B | 4.78B | 3.58B | 3.25B |
| Selling, general and administrative | 1.60B | 2.70B | 2.47B | 2.37B | 1.29B |
| Operating income | -719.5M | 1.52B | -7.65B | -4.86B | -6.97B |
| Depreciation and amortization | 518.5M | 391.9M | 381.9M | 379.1M | 433.5M |
| EBITDA | -201.0M | 1.91B | -7.27B | -4.48B | -6.54B |
| Interest expense | 367.3M | 520.1M | 574.4M | 360.4M | 1.41B |
| Income before tax | -311.1M | 2.86B | -7.52B | -5.73B | -16.6B |
| Net income | -311.1M | 2.86B | -7.52B | -5.73B | -16.6B |
| Earnings per share, basic | -38.28 | 353.61 | -939.24 | -715.76 | -2,078.52 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 6.79B | 308.0K | 262.0K | 491.0K | 22.0B |
| Short-term investments | 30.2B | 36.7B | 10.4B | 11.8B | |
| Receivables | 2.24B | 1.85B | 1.03B | 389.1M | 118.7M |
| Inventory | 3.04B | 2.58B | 2.17B | 1.94B | 1.31B |
| Current assets | 43.3B | 46.9B | 18.0B | 17.5B | 23.7B |
| Property, plant and equipment | 11.3B | 11.4B | 11.7B | ||
| Total assets | 59.3B | 58.8B | 29.6B | 32.1B | 39.7B |
| Accounts payable | 47.7M | 13.4M | 58.2M | 45.0M | 4.10M |
| Current liabilities | 8.04B | 11.9B | 33.8B | 31.0B | 13.0B |
| Long-term debt | 950.7M | 763.5M | 933.5M | 500.0M | |
| Total liabilities | 11.2B | 13.7B | 35.5B | 32.4B | 34.6B |
| Shareholders' equity | 48.1B | 45.2B | -5.90B | -253.8M | 5.08B |
| Shares outstanding | 8.13M | 8.09M | 8.01M | 8.01M | 8.01M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | 1.25B | -1.20B | -4.16B | -8.21B | -5.40B |
| Capital spending | -3.15B | -439.4M | -64.5M | -195.1M | -774.2M |
| Free cash flow | -1.90B | -1.64B | -4.22B | -8.40B | -6.17B |
| Cash from investing | -26.4B | 4.11B | -10.9B | ||
| Cash from financing | 28.3B | 973.6M | 95.2M | ||
| Share buybacks | 28.9B | 484.3M | 46.6M | ||
| Change in cash | 1.84B | 1.05B | 888.1M | -19.0B | 15.3B |
Cap table
Built by 6ix from Nextbiomedical Co. Ltd.’s releases
- Common shares
- 8,277,286
- Fully diluted
- 8,277,286
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 8,277,286 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 8,277,286 |
Log in to ask 6ix AI your own questions about Nextbiomedical Co. Ltd.